Application · Mass Spectrometry Imaging

Blood/Urine Sample Applications: Reading Molecular Space on Body-Fluid Spots

Blood and urine are enriched samples of drugs, metabolites and endogenous biomarkers. Blood/urine sample applications use mass spectrometry imaging (MSI) to present in-situ the spatial distribution of these molecules on blood spots, urine spots and related sections, moving body-fluid analysis from 'overall concentration' to 'intra-spot distribution', serving pharmacokinetics, toxicology and clinical testing.
Table of Contents
1. Entry Point of MSI in Body-Fluid Samples2. Observable Information Types3. Connection with Pharmacokinetics, Toxicology and Clinical4. Interpretation Boundaries and Engineering Deployment
Schematic principle: ion source ionizes the sample spot-by-spot Tissue section Sample Ionization beam Blood/Urine Sample Applications: Reading Molecular Space on Body-Fluid Spots Ions MS analyzer
Blood/Urine Sample Applications: Reading Molecular Space on Body-Fluid Spots — schematic diagram

1. Entry Point of MSI in Body-Fluid Samples

The application notes of the Neo-Source MSI DPI list 'high-throughput rapid analysis and screening (Chinese medicinal materials, blood, natural products, drugs, etc.)' as typical applicable objects, and explicitly state that DPI has no polarity bias, sensitivity 1–4 orders of magnitude higher than traditional DESI, and low ion-suppression effects. These features allow complex body-fluid samples such as blood and urine to be analyzed directly without cumbersome purification.

Its matrix-free, measure-on-demand engineering orientation reduces sample handling from 'half a day at best' to 'measure on demand', which is critical for drug screening and toxicology screening requiring many blood/urine samples.

2. Observable Information Types

In blood/urine-related samples, MSI can present in-situ: the distribution of exogenous drugs and their metabolites, the spatial pattern of endogenous metabolites (e.g., lipids, organic acids), and abnormal enrichment regions. For common evidence such as blood spots and urine spots, imaging can read molecular space without destroying the sample, facilitating preservation and review.

In the DPI case, tests in both positive and negative ion modes compared with traditional DESI could newly detect more than a hundred secondary metabolites, with overall signal enhanced by 1–3 orders of magnitude; this sensitivity advantage also benefits the spatial detection of low-abundance drugs and metabolites in body fluids.

3. Connection with Pharmacokinetics, Toxicology and Clinical

Pharmacokinetic research can use blood/urine samples to track the trajectory of drugs and metabolites; toxicology screening can discover abnormally enriched metabolites or exogenous substances; clinical testing can assist in-situ validation of candidate biomarkers on body-fluid spots. Registering MSI results with histology and LC-MS, or complementing them, forms more complete evidence.

Matrix-free preparation makes such often sample-comparison-heavy scenarios easier to deploy: the two Neo-Source imaging sources are matrix-free and measure on demand, and the section remains intact after imaging for continued H&E or IHC validation.

4. Interpretation Boundaries and Engineering Deployment

MSI gives relative spatial distribution and ion-intensity images; quantification requires standard curves or internal standards, considering sample collection, storage and other background. It excels at localization and discovery; the gold standard for absolute quantification is often complemented by LC-MS.

DPI is engineered to be compatible with mainstream mass spectrometers from Agilent, AB SCIEX and Thermo (MSI DPI-25A/25S/25T), and provides a self-developed titanium-alloy ion transfer tube that does not damage the sample at the front end and is detachable for cleaning, enabling stable and reproducible blood/urine sample MSI.

Frequently Asked Questions (FAQ)

What can MSI see in blood/urine samples?
It can present in-situ the distribution of exogenous drugs and their metabolites, the spatial pattern of endogenous metabolites (lipids, organic acids, etc.), and abnormal enrichment regions.
Why do body-fluid samples value matrix-free and high-throughput?
Body-fluid components are complex and traditionally require purification; DPI is matrix-free, has low ion suppression and measures on demand, suitable for drug screening and toxicology screening of many blood/urine samples.
Can MSI achieve absolute quantification of body-fluid samples?
It mainly provides relative spatial distribution and ion-intensity images; absolute quantification usually requires standard curves, internal standards or LC-MS validation; MSI is strong in localization and discovery.
Can blood/urine MSI results be used directly for clinical diagnosis?
Currently mostly at the research and translation stage; entering clinical use still requires standardization, cohort validation and regulatory procedures; MSI is strong in discovery and in-situ validation.

Get Specifications & Quotation

To obtain detailed specifications, compatible models, or a quotation for the MSI LDPI / DPI full series imaging ion sources, visit the Neo-Source official website, or contact the official team for compatibility advice tailored to your mass spectrometer (Agilent / SCIEX / Thermo and other mainstream MS).

Related Articles

DPI Dual-Photoionization Imaging SourceNeo-Source MSI LDPI Laser Desorption Photoionization imaging ion sourceDrug Metabolism Analysis: Tracking 'Drug' and 'Metabolite' In-SituForensic Field Applications: Letting the Molecules on Evidence 'Speak'Spatial Metabolomics MSI: Bringing Metabolomics into Real Tissue Space

← Back to MSI Ion Source Knowledge Hub